• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why iBio Shares Are Trading Lower By Around 48%; Here Are 23 Stocks Moving Premarket

    12/7/22 7:41:34 AM ET
    $COSM
    $CTRM
    $DUO
    $EGIO
    Other Pharmaceuticals
    Health Care
    Marine Transportation
    Consumer Discretionary
    Get the next $COSM alert in real time by email

    Gainers

    • TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares rose 71.3% to $0.7190 in pre-market trading after the company reported withdrawal of registration statement.
    • The Very Good Food Company Inc. (NASDAQ:VGFC) shares rose 37% to $0.1096 in pre-market trading after droping 17% on Tuesday. Very Good Food recently said it plans to launch its products at Albertsons Companies grocery stores across the U.S.
    • MongoDB, Inc. (NASDAQ:MDB) rose 26.9% to $183.59 in pre-market trading after the company reported better-than-expected sales results. The company also issued Q4 and FY23 EPS and sales guidance above analyst estimates.
    • Scopus BioPharma Inc. (NASDAQ:SCPS) shares rose 19.2% to $0.24 in pre-market trading after dropping around 5% on Tuesday.
    • Meta Materials Inc. (NASDAQ:MMAT) rose 14.9% to $2.24 in pre-market trading after climbing 14% on Tuesday.
    • uCloudlink Group Inc. (NASDAQ:UCL) rose 9% to $3.77 in pre-market trading. UCLOUDLINK recently signed a Memorandum of Understanding with Singapore EV provider Apollo EV to provide high-quality in-vehicle network connectivity solutions.
    • Edgio, Inc. (NASDAQ:EGIO) rose 8% to $1.500 in pre-market trading after dropping 4% on Tuesday. Edgio, last month, reported worse-than-expected Q3 sales results and issued Q4 sales guidance below analyst estimates..
    • KLX Energy Services Holdings, Inc. (NASDAQ:KLXE) rose 7.8% to $15.39 in pre-market trading after declining over 4% on Tuesday.
    • E-Home Household Service Holdings Limited (NASDAQ:EJH) rose 7.7% to $0.5480 in pre-market trading after dropping over 5% on Tuesday.
    • ESS Tech, Inc. (NYSE:GWH) rose 7.7% to $3.08 in pre-market trading after dropping over 13% on Tuesday.


    Don’t forget to check out our premarket coverage here .


    Losers

    • iBio, Inc. (NYSE:IBIO) fell 47.5% to $0.8367 in pre-market trading after the company reported pricing of $3.5 million underwritten public offering of 3,365,385 shares at $1.04 per share.
    • Versus Systems Inc. (NASDAQ:VS) fell 38.6% to $0.9139 in pre-market trading. Versus Systems recently regained compliance with Nasdaq Minimum Bid Price Requirement.
    • Winc, Inc. (NYSE:WBEV) shares fell 29.1% to $0.2482 in pre-market trading after dropping over 15% on Tuesday.
    • X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) shares fell 15% to $1.02 in pre-market trading after the company reported a proposed public offering.
    • Cosmos Holdings Inc. (NASDAQ:COSM) shares fell 12.6% to $0.4109 in pre-market trading after dipping 17% on Tuesday.
    • Fangdd Network Group Ltd. (NASDAQ:DUO) fell 12.6% to $1.10 in pre-market trading after dropping more than 7% on Tuesday.
    • Tuya Inc. (NYSE:TUYA) shares fell 12.4% to $1.34 in pre-market trading after gaining around 12% on Tuesday.
    • Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) fell 12.1% to $0.2050 in pre-market trading.
    • Equillium, Inc. (NASDAQ:EQ) fell 9.5% to $1.50 in pre-market trading. Equillium announced an option and asset purchase agreement through which Ono Pharmaceutical Co Ltd gains the exclusive option to purchase Equillium's rights to itolizumab.
    • Castor Maritime Inc. (NASDAQ:CTRM) fell 9% to $1.42 in pre-market trading.
    • Niu Technologies (NASDAQ:NIU) fell 8.5% to $4.62 in pre-market trading after surging around 15% on Tuesday. Niu Technologies recently reported worse-than-expected Q3 EPS results.
    • GDS Holdings Limited (NYSE:GDS) fell 7.8% to $16.80 in pre-market trading.
    • Kingsoft Cloud Holdings Limited (NASDAQ:KC) fell 7.1% to $3.03 in pre-market trading.
    Get the next $COSM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COSM
    $CTRM
    $DUO
    $EGIO

    CompanyDatePrice TargetRatingAnalyst
    MongoDB Inc.
    $MDB
    2/26/2026$455.00 → $400.00Outperform
    BMO Capital Markets
    Equillium Inc.
    $EQ
    2/25/2026$5.00Buy
    Stifel
    Kingsoft Cloud Holdings Limited
    $KC
    2/11/2026$15.60Neutral → Buy
    Goldman
    MongoDB Inc.
    $MDB
    1/6/2026$480.00 → $500.00Buy
    Needham
    MongoDB Inc.
    $MDB
    12/16/2025Mkt Perform
    Raymond James
    X4 Pharmaceuticals Inc.
    $XFOR
    12/5/2025$10.00Buy
    Stifel
    MongoDB Inc.
    $MDB
    12/2/2025$415.00 → $455.00Outperform
    BMO Capital Markets
    MongoDB Inc.
    $MDB
    12/2/2025$360.00 → $475.00Buy
    Monness Crespi & Hardt
    More analyst ratings

    $COSM
    $CTRM
    $DUO
    $EGIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

    Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

    4/29/24 2:36:51 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COSM
    $CTRM
    $DUO
    $EGIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Goodman Kelly F. sold $3,494 worth of shares (2,269 units at $1.54), decreasing direct ownership by 1% to 215,853 units (SEC Form 4)

    4 - ESS Tech, Inc. (0001819438) (Issuer)

    2/26/26 9:44:48 PM ET
    $GWH
    Industrial Machinery/Components
    Miscellaneous

    Chief Financial Officer Suhadolnik Kate Eileen sold $1,141 worth of shares (741 units at $1.54), decreasing direct ownership by 0.45% to 164,414 units (SEC Form 4)

    4 - ESS Tech, Inc. (0001819438) (Issuer)

    2/26/26 9:45:53 PM ET
    $GWH
    Industrial Machinery/Components
    Miscellaneous

    Sr. Vice President and COO Zedelmayer Christine sold $328,104 worth of shares (185,937 units at $1.76) and exercised 185,937 shares at a strike of $0.76 (SEC Form 4)

    4 - Equillium, Inc. (0001746466) (Issuer)

    2/23/26 12:52:51 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COSM
    $CTRM
    $DUO
    $EGIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets reiterated coverage on MongoDB with a new price target

    BMO Capital Markets reiterated coverage of MongoDB with a rating of Outperform and set a new price target of $400.00 from $455.00 previously

    2/26/26 6:51:04 AM ET
    $MDB
    Computer Software: Prepackaged Software
    Technology

    Stifel initiated coverage on Equillium with a new price target

    Stifel initiated coverage of Equillium with a rating of Buy and set a new price target of $5.00

    2/25/26 7:52:10 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kingsoft Cloud upgraded by Goldman with a new price target

    Goldman upgraded Kingsoft Cloud from Neutral to Buy and set a new price target of $15.60

    2/11/26 7:42:03 AM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    $COSM
    $CTRM
    $DUO
    $EGIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    $CTRM
    $DUO
    $EGIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

    - Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization, under exceptional circumstances, of mavorixafor for the treatment of WHIM syndrome in the European Union (EU). The positive opinion will now be reviewed by the European Commission (EC) with a final approval decision anticipated in the second quarter of 2026. "This po

    2/27/26 7:00:00 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

    LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company's lead therapeutic candidate is EQ504, a po

    2/25/26 8:30:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    $CTRM
    $DUO
    $EGIO
    SEC Filings

    View All

    iBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - iBio, Inc. (0001420720) (Filer)

    2/27/26 4:49:58 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by iBio Inc.

    S-3 - iBio, Inc. (0001420720) (Filer)

    2/27/26 4:23:59 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GDS Holdings Limited

    6-K - GDS Holdings Ltd (0001526125) (Filer)

    2/24/26 8:47:36 AM ET
    $GDS
    Computer Software: Programming Data Processing
    Technology

    $COSM
    $CTRM
    $DUO
    $EGIO
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    ESS Appoints Randall Selesky as Chief Commercial Officer to Accelerate Global Growth

    Veteran Energy Storage Commercial Leader to Drive Global Commercial Execution as ESS Strengthens Leadership Team and Scales Deployments ESS Tech, Inc. (NYSE:GWH) ("ESS" or the "Company"), a leading innovator in long-duration energy storage solutions, today announced that Randall "Randy" Selesky has joined the company as Chief Commercial Officer (CCO). In this role, Selesky will lead global commercial strategy, sales, marketing, product management, and business development initiatives as ESS advances commercialization and scales deployment of its long-duration energy storage solutions worldwide. Selesky joins ESS with more than 20 years of leadership in the energy sector, including more

    2/19/26 8:40:00 AM ET
    $GWH
    Industrial Machinery/Components
    Miscellaneous

    ESS Tech Appoints Drew Buckley as Chief Executive Officer and Announces New Leadership Changes

    Recent Head of Capital Markets Strategy and Veteran Technology Investment Executive to Lead Next Phase of Commercial Execution Interim CEO Kelly Goodman Appointed Chief Strategy Officer and General Counsel Interim CFO Kate Suhadolnik Appointed Permanent Chief Financial Officer ESS Tech, Inc. ("ESS," "ESS, Inc." or the "Company") (NYSE:GWH), a leading manufacturer of long-duration energy storage systems (LDES) for commercial and utility-scale applications, today announced the Board of Directors has appointed Drew Buckley as Chief Executive Officer, effective January 1, 2026, succeeding Interim CEO Kelly Goodman. In addition, the Board appointed Kelly Goodman as Chief Strategy Officer a

    1/6/26 8:31:00 AM ET
    $GWH
    Industrial Machinery/Components
    Miscellaneous

    $COSM
    $CTRM
    $DUO
    $EGIO
    Financials

    Live finance-specific insights

    View All

    ESS Schedules Fourth Quarter and Full Year 2025 Financial Results Conference Call on Thursday, March 5, 2026 at 5:00 p.m. Eastern Time

    ESS Tech, Inc. (ESS) (NYSE: GWH), a leading manufacturer of iron flow long-duration energy storage (LDES) systems for commercial- and utility-scale applications, today announced that it will hold a conference call on Thursday, March 5, 2026 at 5:00 p.m. EST to discuss financial results for its fourth quarter and full year 2025 ended December 31, 2025, and will be providing updates on recent organizational changes, commercial progress and customer deployments, and strategic priorities going forward. A press release detailing these results will be issued prior to the call. ESS Tech CEO Drew Buckley and CFO Kate Suhadolnik will host the conference call, followed by a question-and-answer peri

    2/19/26 8:31:00 AM ET
    $GWH
    Industrial Machinery/Components
    Miscellaneous

    ESS Acquires VoltStorage GmbH Intellectual Property and Assets to Advance Flexible Long-Duration Energy Storage

    Acquisition Expands ESS Technology Portfolio and Strengthens Path to Lower-Cost, Scalable Long-Duration Storage Key VoltStorage Executive and Engineering Personnel Join ESS, Strengthening the Commercial and Technical Bench ESS Tech, Inc. ("ESS" or the "Company"), a leading innovator in long-duration energy storage solutions, today announced the acquisition of the intellectual property and assets of VoltStorage GmbH, a pioneer in iron-salt battery technology. This strategic move combines two complementary technologies to deliver the most flexible, cost-effective long-duration energy storage solution available on the market. The combined platform will set a new industry standard for perfo

    2/18/26 8:31:00 AM ET
    $GWH
    Industrial Machinery/Components
    Miscellaneous

    Tuya to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 2, 2026 Eastern Time

    SANTA CLARA, Calif., Feb. 11, 2026 /PRNewswire/ -- Tuya Inc. ("Tuya" or the "Company") (NYSE:TUYA, HKEX: 2391)), a global leading AI cloud platform service provider, today announced that it will report its unaudited fourth quarter and preliminary fiscal year 2025 financial results after the market closes on Monday, March 2, 2026. Tuya's management will hold a conference call at 07:30 P.M. Eastern Time on Monday, March 2, 2026 (08:30 A.M. Hong Kong Time on Tuesday, March 3, 2026) to discuss the financial results. In advance of the conference call, all participants must use the following links to complete the online registration process. Upon registering, each participant will receive the dia

    2/11/26 5:00:00 AM ET
    $TUYA
    Computer Software: Prepackaged Software
    Technology

    $COSM
    $CTRM
    $DUO
    $EGIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fangdd Network Group Ltd.

    SC 13G - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:26:40 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Fangdd Network Group Ltd.

    SC 13G/A - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:24:27 PM ET
    $DUO
    Real Estate
    Finance

    SEC Form SC 13G filed by Tuya Inc.

    SC 13G - Tuya Inc. (0001829118) (Subject)

    12/4/24 9:00:55 PM ET
    $TUYA
    Computer Software: Prepackaged Software
    Technology